Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin

Arabi, Leila; Badiee, Ali; Mosaffa, Fatemeh; Jaafari, Mahmoud Reza

doi:10.1016/j.jconrel.2015.10.044

Cited by 163 publications

(104 citation statements)

References 74 publications

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…Several approaches have been used to directly target CD44 as a means of inhibiting the CSC population. Anti-CD44 antibodies have been utilized as one means of specifically targeting the CSC population (Arabi et al., 2015, Liu and Jiang, 2006, Molejon et al., 2015). Other approaches to target the CSC population via CD44 have been based on altering transcriptional pathways regulating CD44 expression including Wnt (Yun et al., 2016), FOXP3 (Zhang et al., 2015), SMURF1 (Khammanivong et al., 2014), and Bmi-1 (Yu et al., 2014).…”

Section: Discussionmentioning

confidence: 99%

Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas

et al. 2016

View full text Add to dashboard Cite

SummaryMany solid cancers have an expanded CD44+/hi/CD24−/low cancer stem cell (CSC) population, which are relatively chemoresistant and drive recurrence and metastasis. Achieving a more durable response requires the development of therapies that specifically target CSCs. Recent evidence indicated that inhibiting the SUMO pathway repressed tumor growth and invasiveness, although the mechanism has yet to be clarified. Here, we demonstrate that inhibition of the SUMO pathway repressed MMP14 and CD44 with a concomitant reduction in cell invasiveness and functional loss of CSCs in basal breast cancer. Similar effects were demonstrated with a panel of E1 and E3 SUMO inhibitors. Identical results were obtained in a colorectal cancer cell line and primary colon cancer cells. In both breast and colon cancer, SUMO-unconjugated TFAP2A mediated the effects of SUMO inhibition. These data support the development of SUMO inhibitors as an approach to specifically target the CSC population in breast and colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas

et al. 2016

View full text Add to dashboard Cite

show abstract

“…CD44 is highly expressed in many types of cancers include bladder, breast, colon gastric, glioma, head and neck, osteosarcoma, ovarian, pancreatic, and prostate cancers, as well as leukemia [58][59]. CD44 is being studied as a therapeutic target in metastasizing tumors such as breast and colon cancer [60, 61], and also in leukemia [62]. …”

Section: Introductionmentioning

confidence: 99%

Stemness-related markers in cancer

2017

View full text Add to dashboard Cite

Cancer stem cells (CSCs), with their self-renewal ability and multilineage differentiation potential, are a critical subpopulation of tumor cells that can drive tumor initiation, growth, and resistance to therapy. Like embryonic and adult stem cells, CSCs express markers that are not expressed in normal somatic cells and are thus thought to contribute towards a ‘stemness’ phenotype. This review summarizes the current knowledge of stemness-related markers in human cancers, with a particular focus on important transcription factors, protein surface markers and signaling pathways.

show abstract

“…CD44 (cluster of differentiation 44) is a transmembrane glycoprotein which contains a specific binding domain for hyaluronic acid. CD44 is involved in a series of biological processes, including proliferation, migration, growth, differentiation, and angiogenesis [44]. Various cancers, such as leukemia, ovarian, colon, gastric, pancreatic, and epithelial cancers, have been documented to overexpress CD44.…”

Section: Active Targeting Of Tumor Cellsmentioning

confidence: 99%

“…Other reported methods of targeting the CD44 receptor involve using anti-CD44 monoclonal antibodies [44] or RNA aptamers (e.g., Apt1) [47].…”

Section: Active Targeting Of Tumor Cellsmentioning

confidence: 99%

Liposomal Nanoformulations as Current Tumor-Targeting Approach to Cancer Therapy

Porfire¹,

Achim²,

Tefas³

et al. 2017

Liposomes

View full text Add to dashboard Cite

The liposomes present great potential for applications in targeted delivery of chemotherapeutics in the treatment of cancer. The use of liposomal drug carriers as vehicles for targeting of chemotherapeutic agents to tumor tissues is based on their advantages over other dosage forms, represented by their low systemic toxicity, their bioavailability, and their possibility to enhance the solubility of different chemotherapeutic agents, due to the ability to encapsulate both hydrophilic and lipophilic drugs. They enhance the therapeutic index of anticancer drugs by increasing the drug concentration in tumor cells through tumor targeting. The available approaches used for tumor targeting using liposomes are passive targeting, active targeting, and triggered drug release. The most advanced targeting strategies proposed for cancer treatment are the development of multifunctional liposomes, having combined targeting mechanism. In this chapter, the tumor-targeting mechanisms are described in detail as well as the possibilities to design the targeted liposomal nanocarrier in order to reach the desired target in the body and minimizing the off-target effects. Moreover, the current status of preclinical and clinical evaluation is highlighted.

show abstract

Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin

Cited by 163 publications

References 74 publications

Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas

Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas

Stemness-related markers in cancer

Liposomal Nanoformulations as Current Tumor-Targeting Approach to Cancer Therapy

Contact Info

Product

Resources

About